GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Trump Says Anthropic No Longer Seen as National Security Threat 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
La Chaux-de-Fonds, Switzerland , Dec. 09, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announced today that they have entered into an exclusive, worldwide license agreement with Novartis for the development and commercialization of Rhizen’s, inhaled dual PI3K-delta gamma inhibitor and its closely related compounds for various indications.
Under the terms of the agreement, Rhizen will receive an upfront payment and is eligible to receive development, regulatory and sales milestones payments. In addition Rhizen is also eligible to receive tiered royalties on annual nets sales.
The lead compound is a novel, potent, and selective dual PI3K-delta gamma inhibitor with demonstrated anti-inflammatory and immuno-modulatory activity in pre-clinical systems and models representative of respiratory diseases. With a favorable ADME and PK profile and high therapeutic index in animals, the inhaled dual PI3K-delta gamma inhibitor holds promise in the treatment of human airway disorders.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, www.rhizen.com.
Contact: [email protected]
